Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast
Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast
复制标题
DOI：
10.1309/ga5vrfqfy5d0mvkd
复制
发表时间：
2007-12-01
影响因子：
3.5
通讯作者：
Kim, Aeree
中科院分区：
文献类型：
--
作者：
Lee, Youngseok;Cho, Sujin;Kim, Aeree
通过对378例乳腺浸润性导管癌的临床资料分析，探讨表皮生长因子受体（EGFR）家族成员与乳腺癌预后的关系，发现erbB-3阳性率为13.8%。erbB-3表达与EGFR和erbB-4表达呈负相关（P = 0.012和P = 0.046）。erbB-3的表达与雌激素和孕激素受体阳性状态相关，与组织学分级呈负相关。erbB-3的表达与较长的无病生存期相关（DFS; P = 0.028）。在erbB-3表达组中，与单一表达组相比，共表达组的DFS有缩短的趋势。本研究表明，erbB-3表达与更好的预后相关。在个性化靶向治疗的时代，erbB-3表达及其与其他EGFR家族成员的共表达模式可能是乳腺癌治疗计划的重要决定因素。
The prognostic impact of epidermal growth factor receptor (EGFR) family members in breast carcinoma was evaluated through the analysis of 378 cases of invasive ductal carcinoma to determine the relationship between EGFR family members and clinical outcome.It was found that 13.8% of the cases were positive for erbB-3. Expression of erbB-3 was inversely correlated with EGFR and erbB-4 expression (P =.012 and P =.046). Expression of erbB-3 was correlated with positive estrogen and progesterone receptor status and inversely correlated with histologic grade. Expression of erbB-3 was correlated with longer disease-free survival (DFS; P =.028). Within the erbB-3-expressing group, there was a tendency for the coexpressing group to have shorter DFS compared with the single-expressing group.This study revealed that erbB-3 expression was associated with better prognosis. In an era of personalized targeted therapy, erbB-3 expression and its coexpressive pattern with other EGFR family members could be an important determinant for therapeutic plans for breast cancer treatment.